Scarica l'app Stockscreener
165.15
0.59%
0.97
Pre-mercato:
163.14
-2.01
-1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$164.18
Aprire:
$164.44
Volume 24 ore:
2.12M
Relative Volume:
1.04
Capitalizzazione di mercato:
$315.13B
Reddito:
$54.72B
Utile/perdita netta:
$14.02B
Rapporto P/E:
22.98
EPS:
7.1855
Flusso di cassa netto:
$15.32B
1 W Prestazione:
-1.02%
1M Prestazione:
+8.00%
6M Prestazione:
+28.60%
1 anno Prestazione:
+48.22%
Intervallo 1D:
$162.19
$165.69
Intervallo di 1 settimana:
$160.42
$170.46
Portata 52W:
$97.72
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVS vs LLY, JNJ, ABBV, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
165.15 | 313.28B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
LLY
Lilly Eli Co
|
1,003.57 | 899.90B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.30 | 594.64B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
236.19 | 413.50B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
201.53 | 312.88B | 58.80B | 10.24B | 8.98B | 3.2788 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2026-01-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
What's Driving the Market Sentiment Around Novartis AG? - Sahm
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Finviz
Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month - GlobeNewswire Inc.
NVS Earnings History & Surprises | EPS & Revenue Results | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis stock hits all-time high at 167.87 USD - Investing.com
Stocks To Watch, February 20: Swiggy, IT stocks, crude-sensitive stocks, Novartis India, ABB India, CIE Automotive, Zydus Life - Upstox
Where is Novartis AG (NVS) Headed? - Finviz
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill
A Look Into Novartis Inc's Price Over Earnings - Sahm
Novartis AG stock reaches all-time high at 160.21 USD - Investing.com Nigeria
Novartis AG stock reaches all-time high at 160.21 USD By Investing.com - Investing.com South Africa
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IgA Nephropathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - Barchart.com
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Sahm
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis stock hits all-time high at 153.83 USD By Investing.com - Investing.com Australia
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales - Finviz
Novartis stock hits all-time high at 153.83 USD - Investing.com
Earnings call transcript: Novartis Q4 2025 earnings beat forecasts, stock jumps - Investing.com
Peering Into Novartis AG's Recent Short Interest - Sahm
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Sahm
Why Analysts Are Closely Watching Novartis AG (NVS) - Finviz
Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug - Finviz
Novartis Shares Test 12-Month Highs on Bullish New Outlook - AskTraders.com
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novartis Positions US Strategy As Defense Against Rising Trade Levies - Sahm
Novartis stock hits all-time high at $146.4 By Investing.com - Investing.com South Africa
Novartis stock hits all-time high at $146.4 - Investing.com
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals - Chartmill
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Novartis ADR: Defensive Giant Tests Investor Patience As Rally Cools - AD HOC NEWS
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - Chartmill
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Finviz
The Truth About Novartis AG (ADR): Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Is Novartis AG Gaining or Losing Market Support? - Sahm
3 Dividend Stocks to Buy in 2026 and Hold Forever - Finviz
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):